Eleuterio holds a Ph.D in Biochemistry and Molecular Biology from the Universidad Autónoma de Madrid (Spain) and has more than 30 years of research experience in the fields of virology, innate immunity, inflammation, stem cell biology and cell therapy commercial development. He developed his academic scientific career in some of the most important research institutions in Spain, and The United States (The Salk Institute and The Scripps Research Institute). He joined TiGenix (now part of Takeda) 18 years ago where, as Scientific Director, has been responsible of generating analytical methods for product and process characterization (e.g potency) and a robust non-clinical package that supported the commercialization approval of Alofisel (allogeneic adipose mesenchymal stem cells (ASCs)) for the treatment of complex perianal fistulas in Crohn´s patients in Europe and Japan, and paved the clinical development of ASCs in other indications. Eleuterio is currently leading projects to correlate clinical outcome to product/process characteristics, and to improve cell therapy manufacturing processes through automation.